Publication | Open Access

A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE®

VaccinologyVaccine SafetyVaccinationVaccine DevelopmentThird GenerationImmunologyVaccine TestingVaccine EfficacyVaccine Candidate Imvamune®MedicineVaccine Research